Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2025; 17(6): 105170
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.105170
Efficacy and safety of donafenib plus transarterial chemoembolization and immunotherapy for hepatocellular carcinoma
Zhi-Hao Yang, Si-Nan Liu, Fu-Ying Chu, Cheng Yang, Xiang Chen
Zhi-Hao Yang, Si-Nan Liu, Fu-Ying Chu, Xiang Chen, Department of Laboratory Medicine, Nantong First People’s Hospital and The Second Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001, Jiangsu Province, China
Cheng Yang, Department of Special Treatment, Eastern Hepatobiliary Surgery Hospital, The Affiliated to Naval Medical University, Nantong 226001, Jiangsu Province, China
Co-first authors: Zhi-Hao Yang and Si-Nan Liu.
Co-corresponding authors: Cheng Yang and Xiang Chen.
Author contributions: Yang ZH and Liu SN jointly performed the experiments, analyzed and interpreted the data, organized editing for language and vocabulary, reviewed the article format, analyzed the tools and data, and wrote the paper. The two authors made crucial contributions to the completion of this project, and, therefore, are eligible to be co-first authors thereof. Chu FY contributed reagents, materials, analytical tools, and data. Yang C and Chen X conceived and designed the experiments and wrote the manuscript. This collaboration between Yang C and Chen X is crucial for the publication of this manuscript and other manuscripts still in preparation.
Institutional review board statement: This investigation was approved by the Ethics Committee of the First People’s Hospital of Nantong in 2023 under the ethical review number 2023KT197.
Informed consent statement: All the patients provided written informed consent before inclusion in the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiang Chen, PhD, Department of Laboratory Medicine, Nantong First People’s Hospital and The Second Affiliated Hospital of Nantong University, Medical School of Nantong University, No. 666 Shengli Road, Nantong 226001, Jiangsu Province, China. ntchenx0520@163.com
Received: January 14, 2025
Revised: March 11, 2025
Accepted: April 18, 2025
Published online: June 15, 2025
Processing time: 151 Days and 4.3 Hours
Core Tip

Core Tip: Transarterial chemoembolization combined with donafenib and immune checkpoint inhibitors has been clinically applied in patients with unresectable hepatocellular carcinoma. This study assesses the safety and efficacy of this treatment strategy to better promote the adoption thereof in clinical practice.